Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• Human papillomavirus (HPV)-induced lesions possess targetable foreign antigens crucial for maintaining the cancerous phenotype.
• These characteristics make HPV-induced lesions attractive targets for "proof of concept" studies in therapeutic vaccine development.

Purpose of the Study:

• To review recent clinical trials for immunotherapy of mucosal and cutaneous HPV-induced lesions.
• To discuss emerging therapeutic strategies tested in preclinical models for HPV-induced lesions.

Main Methods:

• Review of recent clinical trials in immunotherapy for HPV lesions.
• Analysis of emerging therapeutic strategies in preclinical models.
• Discussion of various vaccine platforms and therapeutic approaches.

Main Results:

• Recent clinical trials are exploring immunotherapy for HPV-induced lesions.
• Emerging strategies include peptide-based vaccines, DNA-based vaccines, viral/bacterial vector-based vaccines, immune response modifiers, photodynamic therapy, and T cell receptor-based therapy.
• These approaches aim to target HPV-induced cancers.

Conclusions:

• HPV-induced lesions present a promising avenue for therapeutic vaccine development.
• A range of immunotherapy strategies are under investigation, from established vaccine types to novel approaches.
• Further research and clinical trials are essential to advance HPV cancer treatment.